Novartis NVS and AbbVie ABBV announced small M&A deals. The FDA approved the expanded use of Pfizer’s PFE cancer drug Adcetris and a tablet formulation of Roche’s R ...

NEW YORK, February 12, 2025--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for ...

Approval of Adcetris provides a new treatment option for patients with relapsed or refractory large b-cell lymphoma who are ...

Highlights,WCM Investment Management LLC increased its stake in Pfizer, (NYSE:PFE),by 128.7% in the fourth quarter.,Major ...

A council has narrowly voted to withdraw from a controversial housing scheme for more than 10,000 new homes after months of ...

After hours: 7:20:20 p.m. EST ...

Valuation analysis indicates PFE stock is overvalued with a fair share price below $25, and consensus estimates forecast a below 2% dividend growth rate for the next two fiscal years. While Wall ...

Leaked data showed that Pfizer’s mevrometostat has strong therapeutic potential in metastatic castration-resistant prostate ...

The Food and Drug Administration expanded its approval of one of Pfizer's drugs, Adcetris, allowing it to be used as a treatment for certain types of lymphoma.